摘要
目的探析无抽搐电休克(MECT)联合齐拉西酮治疗难治性精神分裂症的临床效果。方法由2018年1月-2019年1月本院接收的难治性精神分裂症患者中选择96例,根据随机数字表法分为参照组和干预组,参照组(n=48)采用齐拉西酮治疗,干预组(n=48)采用齐拉西酮与MECT治疗。比较两组治疗效果、治疗前后的PANSS评分、WMS评分、TESS评分和不良反应发生率。结果治疗后,干预组总疗效显著高于参照组(χ^2=6.0952,P=0.0136),各临床指标评分均低于参照组,差异有统计学意义(t=6.2657,P=0.0000);两组不良反应对比差异无统计学意义10.42%vs16.67%(χ^2=0.8007,P=0.3709)。结论难治性精神分裂症患者临床治疗中联合采用MECT及齐拉西酮治疗作用显著,能有效改善病情,控制不良反应,值得临床推广和应用。
Objective To analyze the clinical effect of non-convulsive electroshock (MECT) combined with ziprasidone in the treatment of refractory schizophrenia. Methods From January 2018 to January 2019, 96 cases of refractory schizophrenia admitted to our hospital were selected. According to the random number table method, they were divided into reference groups and intervention group. The reference group (n=48) received ziprasidone treatment, while the intervention group (n=48) received ziprasidone combined with MECI treatment. The effects of treatment, PANSS score before and after treatment, WMS Score, Tess Score and incidence of adverse reactions were compared between the two groups. Results After treatment, the total curative effect of the intervention group was significantly higher than that of the reference group(χ^2=6.095 2, P=0.013 6). The scores of each clinical index were lower than that of the reference group, and the difference was statistically significant (t=6.265 7, P=0.000 0). There was no significant difference in adverse reactions between the two groups 10.42% vs 16.67%(χ^2=0.800 7, P=0.370 9). Conclusion In the clinical treatment of refractory schizophrenia, the combination of MECT and ziprasidone has a significant effect, which can effectively improve the condition and control adverse reactions. It is worthy of clinical promotion and application.
作者
戴帷幄
DAI Wei-wo(The Fifth People's Hospital of Nanning, Nanning, Guangxi, 530001 China)
出处
《世界复合医学》
2019年第5期22-25,共4页
World Journal of Complex Medicine
关键词
无抽搐电休克
不良反应
精神分裂症
齐拉西酮
Non-convulsive electroshock
Adverse reactions
Schizophrenia
Ziprasidone
